Your browser doesn't support javascript.
loading
Generic Enrichment Method for Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Assay for Quantitative Measurement of Biological Therapeutics in Serum.
Zhang, Sisi; Xiao, Hui; Li, Ning.
Afiliación
  • Zhang S; Regeneron Pharmaceuticals Inc, 777 Old Saw Mill River Road, Tarrytown, New York, 10,591-6706, United States.
  • Xiao H; Regeneron Pharmaceuticals Inc, 777 Old Saw Mill River Road, Tarrytown, New York, 10,591-6706, United States. hui.xiao@regeneron.com.
  • Li N; Regeneron Pharmaceuticals Inc, 777 Old Saw Mill River Road, Tarrytown, New York, 10,591-6706, United States.
Pharm Res ; 41(9): 1881-1892, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39174718
ABSTRACT

PURPOSE:

The study aims to leverage the capabilities of Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry (LC-MRM), a key technique in quantifying therapeutic proteins in pharmacokinetic studies. The focus is on demonstrating an enrichment method using ProteoMiner beads, which can be integrated with LC-MRM to detect low-abundance biotherapeutics in serum, such as monoclonal antibodies and gene therapy products.

METHODS:

The ProteoMiner enrichment method was employed and integrated with LC-MRM. The lower limit of quantification of serum drug substance concentrations was compared with that achievable with immuno-enrichment. The method used commercially available reagents, eliminating the need for assay-specific antibodies and reducing potential bias and development time.

RESULTS:

The ProteoMiner enrichment method showed comparable performance to immuno-enrichment, meeting traditional assay requirements in terms of precision, accuracy, and specificity.

CONCLUSIONS:

The ProteoMiner enrichment method, when combined with LC-MRM, offers a reliable and efficient alternative to immuno-enrichment for detecting and quantifying low-abundance biotherapeutics in serum. This approach, which uses commercially available reagents, can eliminate the bias and time associated with the development of assay-specific antibodies. It holds significant potential for accelerating pharmacokinetic analysis in both early and late stages of pharmaceutical development.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Límite: Animals / Humans Idioma: En Revista: Pharm Res Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Límite: Animals / Humans Idioma: En Revista: Pharm Res Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos